<bill session="114" type="h" number="5314" updated="2018-11-21T21:23:36Z">
  <state datetime="2016-05-24">REFERRED</state>
  <status>
    <introduced datetime="2016-05-24"/>
  </status>
  <introduced datetime="2016-05-24"/>
  <titles>
    <title type="short" as="introduced">Empowering Pharmacists in the Fight Against Opioid Abuse Act</title>
    <title type="official" as="introduced">To provide for the development and dissemination of programs and materials for training pharmacists, health care providers, and patients on the circumstances under which a pharmacist may decline to fill a prescription for a controlled substance because the pharmacist suspects the prescription is fraudulent, forged, or otherwise indicative of abuse or diversion, and for other purposes.</title>
    <title type="display">Empowering Pharmacists in the Fight Against Opioid Abuse Act</title>
  </titles>
  <sponsor bioguide_id="D000623"/>
  <cosponsors>
    <cosponsor bioguide_id="C001103" joined="2016-05-24"/>
  </cosponsors>
  <actions>
    <action datetime="2016-05-24">
      <text>Introduced in House</text>
    </action>
    <action datetime="2016-05-24" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Crime and law enforcement"/>
    <term name="Drug trafficking and controlled substances"/>
    <term name="Fraud offenses and financial crimes"/>
    <term name="Government information and archives"/>
    <term name="Health personnel"/>
    <term name="Health promotion and preventive care"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2016-05-24T04:00:00Z" status="Introduced in House">Empowering Pharmacists in the Fight Against Opioid Abuse Act

This bill requires the Drug Enforcement Administration (DEA) to develop and disseminate training programs and materials on: (1) the circumstances under which a pharmacist may refuse to fill a controlled substance prescription suspected to be fraudulent, forged, or indicative of abuse or diversion; and (2) federal requirements related to such refusal.

The DEA must seek input from relevant stakeholders.</summary>
  <committee-reports/>
</bill>
